Table 2.
The results of antimicrobial susceptibility testing and phenotypic carbapenemase production of the transformant TS37.AK compared to the respective parent clinical isolate K. pneumoniae 37.AK and the untransformed E. coli DH5α
| Parent clinical isolate K. pneumoniae 37.AK | Transformant TS37.AK | Untransformed E. coli DH5α | |
|---|---|---|---|
| Antimicrobial susceptibility testing | |||
| Antimicrobial agent | Phenotypic resistance profile | ||
| Meropenem (10 µg) | R | S | S |
| Imipenem (10 µg) | R | I | S |
| Doripenem (10 µg) | S | S | S |
| Ertapenem (10 µg) | R | S | S |
| Ampicillin/sulbactam (20 µg) | R | R | S |
| Amoxicillin/clavulanic acid (30 µg) | S | S | S |
| Cefepime (30 µg) | R | S | S |
| Ceftriaxone (30 µg) | R | I | S |
| Ceftazidime (30 µg) | R | R | S |
| Cefoxitin (30 µg) | R | R | S |
| Gentamicin (10 µg) | R | S | S |
| Amikacin (30 µg) | R | S | S |
| Levofloxacin (5 µg) | R | S | S |
| Ciprofloxacin (5 µg) | R | S | S |
| Trimethoprim/sulfamethoxazole (25 µg) | R | S | S |
| Fosfomycin (200 µg) | R | S | S |
| Nitrofurantoin (300 µg) | S | S | S |
| Phenotypic detection of carbapenemase production | |||
| Blue-Carba test | +ve | +ve | -ve |
| Modified carbapenem inactivation method (mCIM) | +ve | +ve | -ve |
Abbreviations: S, susceptible; R, resistant; I, intermediate sensitivity.